The Effect of Amantadine on Corneal Endothelium in Subjects with Parkinson's Disease
To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Cross-sectional study. A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls. Endothelial indices we...
Saved in:
Published in | Ophthalmology (Rochester, Minn.) Vol. 117; no. 6; pp. 1214 - 1219 |
---|---|
Main Authors | , , , , , |
Format | Journal Article |
Language | English |
Published |
New York, NY
Elsevier Inc
01.06.2010
Elsevier |
Subjects | |
Online Access | Get full text |
ISSN | 0161-6420 1549-4713 1549-4713 |
DOI | 10.1016/j.ophtha.2009.10.039 |
Cover
Abstract | To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.
Cross-sectional study.
A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls.
Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups.
Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality.
The amantadine group had significantly lower ECD (mean ± standard error; 2662.47±29.06 vs. 2784.72±25.89,
P = 0.002), lower hexagonality (56.94±1.07 vs. 60.97±0.87,
P = 0.004), and greater coefficient of variation (35.59±0.57 vs. 32.66±0.52,
P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (
P<0.05) compared with the normal age-matched control group.
Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term.
The author(s) have no proprietary or commercial interest in any materials discussed in this article. |
---|---|
AbstractList | To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.
Cross-sectional study.
A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls.
Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups.
Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality.
The amantadine group had significantly lower ECD (mean ± standard error; 2662.47±29.06 vs. 2784.72±25.89,
P = 0.002), lower hexagonality (56.94±1.07 vs. 60.97±0.87,
P = 0.004), and greater coefficient of variation (35.59±0.57 vs. 32.66±0.52,
P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (
P<0.05) compared with the normal age-matched control group.
Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term.
The author(s) have no proprietary or commercial interest in any materials discussed in this article. Objective To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Design Cross-sectional study. Participants A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls. Methods Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups. Main Outcome Measures Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality. Results The amantadine group had significantly lower ECD (mean ± standard error; 2662.47±29.06 vs. 2784.72±25.89, P = 0.002), lower hexagonality (56.94±1.07 vs. 60.97±0.87, P = 0.004), and greater coefficient of variation (35.59±0.57 vs. 32.66±0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD ( P <0.05) compared with the normal age-matched control group. Conclusions Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term. Financial Disclosure(s) The author(s) have no proprietary or commercial interest in any materials discussed in this article. To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.OBJECTIVETo evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.Cross-sectional study.DESIGNCross-sectional study.A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls.PARTICIPANTSA total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls.Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups.METHODSEndothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups.Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality.MAIN OUTCOME MEASURESSlit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality.The amantadine group had significantly lower ECD (mean +/- standard error; 2662.47+/-29.06 vs. 2784.72+/-25.89, P = 0.002), lower hexagonality (56.94+/-1.07 vs. 60.97+/-0.87, P = 0.004), and greater coefficient of variation (35.59+/-0.57 vs. 32.66+/-0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (P<0.05) compared with the normal age-matched control group.RESULTSThe amantadine group had significantly lower ECD (mean +/- standard error; 2662.47+/-29.06 vs. 2784.72+/-25.89, P = 0.002), lower hexagonality (56.94+/-1.07 vs. 60.97+/-0.87, P = 0.004), and greater coefficient of variation (35.59+/-0.57 vs. 32.66+/-0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (P<0.05) compared with the normal age-matched control group.Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term.CONCLUSIONSAmantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term. To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Cross-sectional study. A total of 169 subjects (169 eyes) taking amantadine orally for Parkinson's disease and the same number of age- and gender-matched controls. Endothelial indices were compared between the amantadine-treated and age-matched control groups. The amantadine-treated group was divided into 3 subgroups according to the cumulative dose and duration of treatment. Endothelial changes were compared between the amantadine group and the normal control group, and among subgroups. Slit-lamp biomicroscopy, central corneal thickness (CCT), endothelial cell density (ECD), coefficient of variation, and hexagonality. The amantadine group had significantly lower ECD (mean +/- standard error; 2662.47+/-29.06 vs. 2784.72+/-25.89, P = 0.002), lower hexagonality (56.94+/-1.07 vs. 60.97+/-0.87, P = 0.004), and greater coefficient of variation (35.59+/-0.57 vs. 32.66+/-0.52, P = 0.000) compared with the age-matched control group. Longer duration and higher cumulative dose amantadine therapy led to a greater reduction in ECD (P<0.05) compared with the normal age-matched control group. Amantadine is more likely to have an effect on corneal endothelial cells in a dose-dependent manner when used long-term. |
Author | Chang, Ki Cheol Lee, Jin Hak Wee, Won Ryang Kim, Mee Kum Jeong, Jin Ho Jeon, Beom Seok |
Author_xml | – sequence: 1 givenname: Ki Cheol surname: Chang fullname: Chang, Ki Cheol organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea – sequence: 2 givenname: Jin Ho surname: Jeong fullname: Jeong, Jin Ho organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea – sequence: 3 givenname: Mee Kum surname: Kim fullname: Kim, Mee Kum organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea – sequence: 4 givenname: Won Ryang surname: Wee fullname: Wee, Won Ryang email: wrwee@snu.ac.kr organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea – sequence: 5 givenname: Jin Hak surname: Lee fullname: Lee, Jin Hak organization: Department of Ophthalmology, Seoul National University College of Medicine, Seoul, Korea – sequence: 6 givenname: Beom Seok surname: Jeon fullname: Jeon, Beom Seok organization: Department of Neurology, Seoul National University College of Medicine, Seoul, Korea |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22879951$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/20153901$$D View this record in MEDLINE/PubMed |
BookMark | eNqVkl9rFDEUxYO02G31G4jkRfo022Qy_yIilHW1hYJC1-eQSe4wmc4ka5JR-u3NsKuCIMWncC-_c5Occ8_RiXUWEHpFyZoSWl0Na7fvYy_XOSE8tdaE8WdoRcuCZ0VN2QlaJYxmVZGTM3QewkAIqSpWPEdnOaEl44Su0G7XA952HaiIXYevJ2mj1MYCdhZvnLcgR7y12sUeRjNP2Fh8P7dD4gP-YWKPv0j_YGxw9jLgDyaADPACnXZyDPDyeF6grx-3u81Ndvf50-3m-i5TBecxY6UiWudKpye2sgMm66olrNNVSTk0UOqcsyKVtAQtuZKpboqm1FDUqmMtu0CXh7l7777NEKKYTFAwjtKCm4OoGaNNyWieyNdHcm4n0GLvzST9o_hlRALeHAEZlBw7L60y4Q-XNzXn5cIVB055F4KH7jdCiVhyEYM45CKWXJZuyiXJ3v4lUybKaJyNXprxKfH7gxiSl98NeBGUAatAG59yENqZ_x2gRmNN-ucDPEIY3OxtyklQEXJBxP2yN8vakORMXvPFvnf_HvD0_T8B3u7T6g |
CODEN | OPHTDG |
CitedBy_id | crossref_primary_10_1016_j_baga_2013_09_001 crossref_primary_10_1016_j_jcjo_2013_12_010 crossref_primary_10_1016_j_pmrj_2018_03_007 crossref_primary_10_1097_ICO_0000000000001951 crossref_primary_10_1007_s00702_018_1869_1 crossref_primary_10_52725_aocl_2024_23_2_76 crossref_primary_10_1097_ICO_0b013e31823f8af4 crossref_primary_10_1016_j_ajo_2021_05_020 crossref_primary_10_1186_s12886_022_02410_1 crossref_primary_10_1016_j_oftal_2011_09_007 crossref_primary_10_1016_j_exer_2019_02_010 crossref_primary_10_1016_j_ajo_2016_08_034 crossref_primary_10_1016_j_oftale_2011_09_005 crossref_primary_10_15446_revfacmed_v65n3_56637 crossref_primary_10_4103_IJO_IJO_1149_23 crossref_primary_10_1038_s41433_019_0497_9 crossref_primary_10_3389_fneur_2023_1236366 crossref_primary_10_1016_j_ajoc_2020_100852 crossref_primary_10_3390_life12122141 crossref_primary_10_1016_j_exer_2024_110225 crossref_primary_10_1080_00207454_2020_1761353 crossref_primary_10_1016_j_ajoc_2023_101881 crossref_primary_10_14802_jmd_13008 crossref_primary_10_17116_jnevro2021121041101 |
Cites_doi | 10.1097/01.ico.0000130417.91438.7e 10.1016/0002-9394(84)90120-X 10.1002/mds.22136 10.1097/00003226-199004000-00017 10.1212/WNL.25.8.695 10.1007/BF00839973 10.1016/j.ophtha.2008.03.011 10.1097/ICO.0b013e3181450d4c 10.1111/j.1468-1331.2005.01025.x 10.1212/WNL.50.5.1323 10.1097/ICO.0b013e318180e526 10.1007/s004170000223 10.1001/jama.237.12.1200a 10.1016/j.parkreldis.2007.03.003 10.1016/0002-9394(86)90209-6 10.1097/ICO.0b013e318033a6da 10.1016/S0002-9394(14)76952-1 |
ContentType | Journal Article |
Copyright | 2010 American Academy of Ophthalmology American Academy of Ophthalmology 2015 INIST-CNRS Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
Copyright_xml | – notice: 2010 American Academy of Ophthalmology – notice: American Academy of Ophthalmology – notice: 2015 INIST-CNRS – notice: Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
DBID | AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.ophtha.2009.10.039 |
DatabaseName | CrossRef Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1549-4713 |
EndPage | 1219 |
ExternalDocumentID | 20153901 22879951 10_1016_j_ophtha_2009_10_039 S0161642009012792 1_s2_0_S0161642009012792 |
Genre | Journal Article |
GroupedDBID | --- --K .1- .55 .FO .GJ 0R~ 123 1B1 1CY 1P~ 1~5 29N 4.4 457 4G. 53G 5RE 5VS 7-5 71M AAEDT AAEDW AALRI AAQFI AAQQT AAQXK AAXUO ABCQX ABFRF ABJNI ABLJU ABMAC ABOCM ABWVN ACGFO ACGFS ACIUM ACNCT ACRPL ACVFH ADCNI ADMUD ADNMO AEFWE AENEX AEUPX AEVXI AFFNX AFJKZ AFPUW AFRHN AFTJW AGCQF AGQPQ AIGII AITUG AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMRAJ BELOY C5W CS3 DU5 EBS EFJIC EFKBS EJD F5P FDB FEDTE FGOYB GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B M27 M41 MO0 N4W N9A NQ- O9- OF- OPF OQ~ P2P R2- ROL RPZ SDG SEL SES SSZ UHS UNMZH UV1 WH7 X7M XH2 XPP Z5R ZGI ZXP ADPAM RIG AAIAV AGZHU AHPSJ ALXNB ZA5 AAYXX CITATION IQODW CGR CUY CVF ECM EIF NPM 7X8 |
ID | FETCH-LOGICAL-c499t-35c0dd2cd642bafe3a76b03fd6519e8e5d2934fd615eda9cad298485de47cf3b3 |
ISSN | 0161-6420 1549-4713 |
IngestDate | Sun Sep 28 10:28:09 EDT 2025 Mon Jul 21 05:59:13 EDT 2025 Mon Jul 21 09:14:09 EDT 2025 Tue Jul 01 01:01:31 EDT 2025 Thu Apr 24 23:07:36 EDT 2025 Fri Feb 23 02:17:05 EST 2024 Sun Feb 23 10:19:56 EST 2025 Tue Aug 26 19:02:59 EDT 2025 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 6 |
Keywords | Human Agonist Nervous system diseases Amantadine Cornea Dopamine receptor Parkinson disease Glutamate receptor Antiparkinson agent Cerebral disorder Endothelium Amantadine derivatives Central nervous system disease Dopamine agonist Antiviral Degenerative disease Antagonist Ophthalmology NMDA receptor Extrapyramidal syndrome |
Language | English |
License | https://www.elsevier.com/tdm/userlicense/1.0 CC BY 4.0 Copyright 2010 American Academy of Ophthalmology. Published by Elsevier Inc. All rights reserved. |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c499t-35c0dd2cd642bafe3a76b03fd6519e8e5d2934fd615eda9cad298485de47cf3b3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 20153901 |
PQID | 733185312 |
PQPubID | 23479 |
PageCount | 6 |
ParticipantIDs | proquest_miscellaneous_733185312 pubmed_primary_20153901 pascalfrancis_primary_22879951 crossref_primary_10_1016_j_ophtha_2009_10_039 crossref_citationtrail_10_1016_j_ophtha_2009_10_039 elsevier_sciencedirect_doi_10_1016_j_ophtha_2009_10_039 elsevier_clinicalkeyesjournals_1_s2_0_S0161642009012792 elsevier_clinicalkey_doi_10_1016_j_ophtha_2009_10_039 |
ProviderPackageCode | CITATION AAYXX |
PublicationCentury | 2000 |
PublicationDate | 2010-06-01 |
PublicationDateYYYYMMDD | 2010-06-01 |
PublicationDate_xml | – month: 06 year: 2010 text: 2010-06-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New York, NY |
PublicationPlace_xml | – name: New York, NY – name: United States |
PublicationTitle | Ophthalmology (Rochester, Minn.) |
PublicationTitleAlternate | Ophthalmology |
PublicationYear | 2010 |
Publisher | Elsevier Inc Elsevier |
Publisher_xml | – name: Elsevier Inc – name: Elsevier |
References | Pearlman, Kadish, Ramseyer (bib1) 1977; 237 Fraunfelder, Meyer (bib3) 1990; 110 Lee, Park, Lee (bib17) 2001; 239 Mac Rae, Matsuda, Shellans, Rich (bib16) 1986; 102 Sheng, Bullimore (bib15) 2007; 26 Jeng, Galor, Lee (bib7) 2008; 115 French, Margo (bib14) 2007; 26 Chang, Kim, Wee, Lee (bib8) 2008; 27 Nogaki, Morimatsu (bib4) 1993; 240 Kubo, Iwatake, Ebihara (bib6) 2008; 14 Ray, O'Day (bib11) 1985; 26 Schultz, Matsuda, Yee (bib18) 1984; 98 Hughes, Feiz, Flynn, Brodsky (bib5) 2004; 23 Dubow, Rezak, Berman (bib9) 2008; 23 Hadjikoutis, Morgan, Wild, Smith (bib10) 2005; 12 Fahn, Isgreen (bib12) 1975; 25 Verhagen Metman, Del Potto, van den Munckhof (bib13) 1998; 50 Blanchard (bib2) 1990; 9 Nogaki (10.1016/j.ophtha.2009.10.039_bib4) 1993; 240 Hadjikoutis (10.1016/j.ophtha.2009.10.039_bib10) 2005; 12 Fahn (10.1016/j.ophtha.2009.10.039_bib12) 1975; 25 Kubo (10.1016/j.ophtha.2009.10.039_bib6) 2008; 14 Schultz (10.1016/j.ophtha.2009.10.039_bib18) 1984; 98 Chang (10.1016/j.ophtha.2009.10.039_bib8) 2008; 27 Dubow (10.1016/j.ophtha.2009.10.039_bib9) 2008; 23 Blanchard (10.1016/j.ophtha.2009.10.039_bib2) 1990; 9 Fraunfelder (10.1016/j.ophtha.2009.10.039_bib3) 1990; 110 Verhagen Metman (10.1016/j.ophtha.2009.10.039_bib13) 1998; 50 Mac Rae (10.1016/j.ophtha.2009.10.039_bib16) 1986; 102 Hughes (10.1016/j.ophtha.2009.10.039_bib5) 2004; 23 Sheng (10.1016/j.ophtha.2009.10.039_bib15) 2007; 26 Jeng (10.1016/j.ophtha.2009.10.039_bib7) 2008; 115 Ray (10.1016/j.ophtha.2009.10.039_bib11) 1985; 26 French (10.1016/j.ophtha.2009.10.039_bib14) 2007; 26 Lee (10.1016/j.ophtha.2009.10.039_bib17) 2001; 239 Pearlman (10.1016/j.ophtha.2009.10.039_bib1) 1977; 237 |
References_xml | – volume: 102 start-page: 50 year: 1986 end-page: 57 ident: bib16 article-title: The effects of hard and soft contact lenses on the corneal endothelium publication-title: Am J Ophthalmol – volume: 23 start-page: 823 year: 2004 end-page: 824 ident: bib5 article-title: Reversible amantadine-induced corneal edema in an adolescent publication-title: Cornea – volume: 26 start-page: 1087 year: 2007 end-page: 1089 ident: bib14 article-title: Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration publication-title: Cornea – volume: 239 start-page: 1 year: 2001 end-page: 4 ident: bib17 article-title: A comparative study of corneal endothelial changes induced by different durations of soft contact lens wear publication-title: Graefes Arch Clin Exp Ophthalmol – volume: 237 start-page: 1200 year: 1977 ident: bib1 article-title: Vision loss associated with amantadine hydrochloride use [letter] publication-title: JAMA – volume: 115 start-page: 1540 year: 2008 end-page: 1544 ident: bib7 article-title: Amantadine-associated corneal edema: potentially irreversible even after cessation of the medication publication-title: Ophthalmology – volume: 23 start-page: 2096 year: 2008 end-page: 2097 ident: bib9 article-title: Reversible corneal edema associated with amantadine use: an unrecognized problem [letter] publication-title: Mov Disord – volume: 50 start-page: 1323 year: 1998 end-page: 1326 ident: bib13 article-title: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease publication-title: Neurology – volume: 14 start-page: 166 year: 2008 end-page: 169 ident: bib6 article-title: Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature publication-title: Parkinsonism Relat Disord – volume: 26 start-page: 520 year: 2007 end-page: 525 ident: bib15 article-title: Factors affecting corneal endothelial morphology publication-title: Cornea – volume: 110 start-page: 96 year: 1990 end-page: 97 ident: bib3 article-title: Amantadine and corneal deposits publication-title: Am J Ophthalmol – volume: 12 start-page: 499 year: 2005 end-page: 507 ident: bib10 article-title: Ocular complications of neurological therapy publication-title: Eur J Neurol – volume: 9 start-page: 181 year: 1990 ident: bib2 article-title: Amantadine caused corneal edema [letter] publication-title: Cornea – volume: 240 start-page: 388 year: 1993 end-page: 389 ident: bib4 article-title: Superficial punctate keratitis and corneal abrasion due to amantadine hydrochloride [letter] publication-title: J Neurol – volume: 27 start-page: 1182 year: 2008 end-page: 1185 ident: bib8 article-title: Corneal endothelial dysfunction associated with amantadine toxicity publication-title: Cornea – volume: 25 start-page: 695 year: 1975 end-page: 700 ident: bib12 article-title: Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses publication-title: Neurology – volume: 26 start-page: 1186 year: 1985 end-page: 1188 ident: bib11 article-title: Statistical analysis of multi-eye data in ophthalmic research publication-title: Invest Ophthalmol Vis Sci – volume: 98 start-page: 401 year: 1984 end-page: 410 ident: bib18 article-title: Corneal endothelial changes in type I and type II diabetes mellitus publication-title: Am J Ophthalmol – volume: 23 start-page: 823 year: 2004 ident: 10.1016/j.ophtha.2009.10.039_bib5 article-title: Reversible amantadine-induced corneal edema in an adolescent publication-title: Cornea doi: 10.1097/01.ico.0000130417.91438.7e – volume: 98 start-page: 401 year: 1984 ident: 10.1016/j.ophtha.2009.10.039_bib18 article-title: Corneal endothelial changes in type I and type II diabetes mellitus publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(84)90120-X – volume: 23 start-page: 2096 year: 2008 ident: 10.1016/j.ophtha.2009.10.039_bib9 article-title: Reversible corneal edema associated with amantadine use: an unrecognized problem [letter] publication-title: Mov Disord doi: 10.1002/mds.22136 – volume: 9 start-page: 181 year: 1990 ident: 10.1016/j.ophtha.2009.10.039_bib2 article-title: Amantadine caused corneal edema [letter] publication-title: Cornea doi: 10.1097/00003226-199004000-00017 – volume: 26 start-page: 1186 year: 1985 ident: 10.1016/j.ophtha.2009.10.039_bib11 article-title: Statistical analysis of multi-eye data in ophthalmic research publication-title: Invest Ophthalmol Vis Sci – volume: 25 start-page: 695 year: 1975 ident: 10.1016/j.ophtha.2009.10.039_bib12 article-title: Long-term evaluation of amantadine and levodopa combination in parkinsonism by double-blind crossover analyses publication-title: Neurology doi: 10.1212/WNL.25.8.695 – volume: 240 start-page: 388 year: 1993 ident: 10.1016/j.ophtha.2009.10.039_bib4 article-title: Superficial punctate keratitis and corneal abrasion due to amantadine hydrochloride [letter] publication-title: J Neurol doi: 10.1007/BF00839973 – volume: 115 start-page: 1540 year: 2008 ident: 10.1016/j.ophtha.2009.10.039_bib7 article-title: Amantadine-associated corneal edema: potentially irreversible even after cessation of the medication publication-title: Ophthalmology doi: 10.1016/j.ophtha.2008.03.011 – volume: 26 start-page: 1087 year: 2007 ident: 10.1016/j.ophtha.2009.10.039_bib14 article-title: Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration publication-title: Cornea doi: 10.1097/ICO.0b013e3181450d4c – volume: 12 start-page: 499 year: 2005 ident: 10.1016/j.ophtha.2009.10.039_bib10 article-title: Ocular complications of neurological therapy publication-title: Eur J Neurol doi: 10.1111/j.1468-1331.2005.01025.x – volume: 50 start-page: 1323 year: 1998 ident: 10.1016/j.ophtha.2009.10.039_bib13 article-title: Amantadine as treatment for dyskinesias and motor fluctuations in Parkinson's disease publication-title: Neurology doi: 10.1212/WNL.50.5.1323 – volume: 27 start-page: 1182 year: 2008 ident: 10.1016/j.ophtha.2009.10.039_bib8 article-title: Corneal endothelial dysfunction associated with amantadine toxicity publication-title: Cornea doi: 10.1097/ICO.0b013e318180e526 – volume: 239 start-page: 1 year: 2001 ident: 10.1016/j.ophtha.2009.10.039_bib17 article-title: A comparative study of corneal endothelial changes induced by different durations of soft contact lens wear publication-title: Graefes Arch Clin Exp Ophthalmol doi: 10.1007/s004170000223 – volume: 237 start-page: 1200 year: 1977 ident: 10.1016/j.ophtha.2009.10.039_bib1 article-title: Vision loss associated with amantadine hydrochloride use [letter] publication-title: JAMA doi: 10.1001/jama.237.12.1200a – volume: 14 start-page: 166 year: 2008 ident: 10.1016/j.ophtha.2009.10.039_bib6 article-title: Visual impairment in Parkinson's disease treated with amantadine: case report and review of the literature publication-title: Parkinsonism Relat Disord doi: 10.1016/j.parkreldis.2007.03.003 – volume: 102 start-page: 50 year: 1986 ident: 10.1016/j.ophtha.2009.10.039_bib16 article-title: The effects of hard and soft contact lenses on the corneal endothelium publication-title: Am J Ophthalmol doi: 10.1016/0002-9394(86)90209-6 – volume: 26 start-page: 520 year: 2007 ident: 10.1016/j.ophtha.2009.10.039_bib15 article-title: Factors affecting corneal endothelial morphology publication-title: Cornea doi: 10.1097/ICO.0b013e318033a6da – volume: 110 start-page: 96 year: 1990 ident: 10.1016/j.ophtha.2009.10.039_bib3 article-title: Amantadine and corneal deposits publication-title: Am J Ophthalmol doi: 10.1016/S0002-9394(14)76952-1 |
SSID | ssj0006634 |
Score | 2.1282 |
Snippet | To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.
Cross-sectional study.
A total of 169 subjects (169... Objective To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease. Design Cross-sectional study. Participants A... To evaluate the effect of amantadine on corneal endothelial cells in subjects with Parkinson's disease.OBJECTIVETo evaluate the effect of amantadine on corneal... |
SourceID | proquest pubmed pascalfrancis crossref elsevier |
SourceType | Aggregation Database Index Database Enrichment Source Publisher |
StartPage | 1214 |
SubjectTerms | Adult Aged Amantadine - adverse effects Antiparkinson Agents - adverse effects Biological and medical sciences Cell Count Corneal Diseases - chemically induced Corneal Diseases - pathology Cross-Sectional Studies Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases Dose-Response Relationship, Drug Endothelium, Corneal - drug effects Endothelium, Corneal - pathology Female Humans Male Medical sciences Middle Aged Miscellaneous Nervous system (semeiology, syndromes) Nervous system as a whole Neurology Ophthalmology Parkinson Disease - drug therapy |
Title | The Effect of Amantadine on Corneal Endothelium in Subjects with Parkinson's Disease |
URI | https://www.clinicalkey.com/#!/content/1-s2.0-S0161642009012792 https://www.clinicalkey.es/playcontent/1-s2.0-S0161642009012792 https://dx.doi.org/10.1016/j.ophtha.2009.10.039 https://www.ncbi.nlm.nih.gov/pubmed/20153901 https://www.proquest.com/docview/733185312 |
Volume | 117 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
journalDatabaseRights | – providerCode: PRVLSH databaseName: Elsevier Journals customDbUrl: mediaType: online eissn: 1549-4713 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0006634 issn: 0161-6420 databaseCode: AKRWK dateStart: 19930801 isFulltext: true providerName: Library Specific Holdings |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZCmMwxu7LLkUPgz0UBd8vjyXrKA3ZoEtJ34RiySQhsUOdPGw_b79s51iSkywN7fpiYkeyLZ3P0tHRd84h5HMOk2aSxQ4LRZKxQDohS_3MZ0Ee5n4sgtQXNdvie3R-FVxch9et1p8t1tJ6Ne5mv2_1K3mIVOEayBW9ZP9Dss1N4QL8BvnCESQMx3vL2IQfRoVyAb2ElHiFOwC98qaogwYXEp2s5tP1Am0bMFDMagJHbYBFn2fj_hVXGImz2awx-uqP5WQ1EfOFjtRUmxtMhi3NuS-K7pYtoWetz_3pSW-idPKuQcMpvlCW_4sBtsrdP01a54FSJ32de3nwVVt8miIjTRoaQesuf5kn7RYy5gvcebc0K2vRjFwGiyBnZ0jW_pwGe9sDrOtpn1MzWbtmwN2bCLRNYtYt627ScUmRxacjJ-3G3T7r9V1WeV2H_cS3wZdxUtyS11n6_onH7fLK4w7fK_qIHHlxFHltcnTavxz1G30AdDoTYV431Dpw1izD_fc7pCA9XYoKPttc51s5vCCqFaPhc_LMrGjoqYbnC9JSxUvyeGA4G6_IEFBKNUppmdMNSmlZUINSuoVSOi2oRSlFlNIGpV8qajD6mlx9Oxv2zpnJ5cEyWFOvmB9mjpReJqEHxiJXvoijsePnMoIlhEpUKEHvDODUDZUUaSbgPAmSUKogznJ_7L8h7aIs1DtCQYHFnAOuE-cycDyVShfmkTxOc4EOo2GH-LYDeWYC3WO-lTm3jMYZ192OOVhTvArd3iGsqbXUgV7uKB9a2XDrxAzTLgcA3lEvvq2eqsy4UvFDANuuadRjrfbe45nHO-BpGuh5CQaEdDuEWjRxmF5wz1AUqlxXHFO6gkbvwtPfapRtKoMg0GL6_sEt-kCebIaEj6S9ulmrT6Djr8bH5iP6C_Vq8Xw |
linkProvider | Library Specific Holdings |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Effect+of+Amantadine+on+Corneal+Endothelium+in+Subjects+with+Parkinson%27s+Disease&rft.jtitle=Ophthalmology+%28Rochester%2C+Minn.%29&rft.au=Chang%2C+Ki+Cheol%2C+MD&rft.au=Jeong%2C+Jin+Ho%2C+MD&rft.au=Kim%2C+Mee+Kum%2C+MD%2C+PhD&rft.au=Wee%2C+Won+Ryang%2C+MD%2C+PhD&rft.date=2010-06-01&rft.issn=0161-6420&rft.volume=117&rft.issue=6&rft.spage=1214&rft.epage=1219&rft_id=info:doi/10.1016%2Fj.ophtha.2009.10.039&rft.externalDBID=ECK1-s2.0-S0161642009012792&rft.externalDocID=1_s2_0_S0161642009012792 |
thumbnail_m | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=https%3A%2F%2Fcdn.clinicalkey.com%2Fck-thumbnails%2F01616420%2FS0161642009X00199%2Fcov150h.gif |